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kun.zhang@charite.deSummaryNeuroendocrine tumours (NETs) represent a broad spectrum of tumours, of which the serotonin-producing carcinoid is the
most common and has been shown to cause right ventricular heart failure. However, an association between heart failure
and NETs other than carcinoid has not been established so far. In this case report, we describe a 51-year-old patient with a
glucagon-producing NET of the pancreas who developed acute heart failure and even cardiogenic shock despite therapy.
Heart failure eventually regressed after initialising i.v. treatment with the somatostatin analogue octreotide. Chromogranin
A as a tumour marker was shown to be significantly elevated, and it decreased with clinical improvement of the patient. The
effects of long-time stimulation of glucagon on the myocardium have not been studied yet; however, sarcoplasmic reticulum
calcium leak can be discussed as a possible mechanism for glucagon-induced heart failure.Learning points:
† Glucagonoma can be a cause for heart failure.
† i.v. infusion of octreotide can be successfully used to treat glucagonoma-induced acute heart failure.
† We suggest that cardiac function should be monitored in all NET patients.Background
Neuroendocrine tumours (NET) cover a broad spectrum of
different hormone-secreting tumours of the neuroendo-
crine system. Among them, the serotonin-producing
carcinoid occurs most commonly. It is known that
progressed stage carcinoid can cause endocard fibrosis of
the right heart leading to pulmonary valve stenosis and
tricuspid valve insufficiency, subsequently leading to right
ventricular heart failure (1). Overproduction of serotonin
is proposed to be causal; however, the pathogenesis is
still incompletely understood. NETs other than carcinoid
have not been linked with heart disease yet.
Within the NETs, glucagon-producing tumours of
the pancreas are fairly rare and can be associated with
syndromes such as MEN1. Clinical manifestations of
glucagonoma include necrolytic migratory erythema,loss of weight, local symptoms due to tumour growth,
anaemia, diabetes mellitus, diarrhoea and thrombo-
embolism (2). Localised glucagonoma without metastases
show a good prognosis after surgical removal, whereas
metastases imply a rather poor prognostic outcome (3).
In this case, we report on a patient with glucagonoma
who presented with left ventricular heart failure and
developed cardiogenic shock. Diagnostics and literature
review led to the differential diagnosis of glucagonoma-
induced heart failure. It is the second case described in the
literature so far.Case presentation
We report on a 51-year-old female patient with MEN1
syndromecharacterised by aheterozygousQ453Xmutationhttp://www.edmcasereports.com
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hyperparathyroidism and a pancreatic tumour, she under-
went parathyroidectomy andpancreatic tail resection in the
past. Histopathology of the pancreatic tumour revealed a
glucagonoma with positive immunostaining for glucagon,
chromogranin A and synaptophysin; negative immuno-
staining for gastrin, insulin, serotonin, somatostatin and
pancreatic polypeptide. Moreover, the tumour showed
the expression of somatostatin receptor type 2 (SSTR2),
implicating responsiveness to somatostatin analogue
therapy. As comorbidity, a multifactorial terminal kidney
failure with haemodialysis three times a week has existed
for almost 3 years. In the further course of disease, the
glucagonoma relapsed with hepatic metastases, currently
controlled as a stable disease under conservative treatment
using everolimus 10 mg/day p.o. and octreotide long-acting
release (LAR) 30 mg i.m. every 3 weeks.
In the present case, the patient came to the emergency
roomwith dyspnoea and cough. Based on atypical bilateral
infiltrations in the X-ray and highly elevated c-reactive
protein (CRP), she was hospitalised with the diagnosis of
pneumonia and treated with antibiotics while everolimus
was paused; the last octreotide LAR injection was given
2 weeks prior to this. In the following days, her symptoms
improved with normalising infection parameters. After
10 days of hospitalisation, however, her condition rapidly
declined with progressive dyspnoea, orthopnoea and
somnolence leading to admission to the intensive care unit.
On admission, the patient showed sinus tachycardia
and hypotension. Echocardiography revealed acute heart
failure with a severely impaired left ventricular ejection
fraction (LVEF) of 10%. Heart disease was not known
previously. Only moderate valvular dysfunction and no
significant hypertrophy or dilatation was seen indicating a
rather recent development of heart disease. Infusions with
dobutamine and nitroprusside sodium were immediately
started, but could not improve LVEF. Despite treatment,
the patient developed cardiogenic shock, leading to
intubation. By using PiCCO technology for haemody-
namicmeasurements, we could confirm cardiogenic shock
and clearly ruled out septic shock based on the following
data: severely decreased cardiac index of 0.8 l/min per m2
(reference 3–5 l/min per m2), highly elevated systemic
vascular resistance index of 3800 dyn!s!cmK5!m2
(reference 1700–2500 dyn!s!cmK5!m2).Investigation
Angiography ruled out coronary artery disease. Myocardial
biopsy showed hypertrophy of cardiomyocytes and slighthttp://www.edmcasereports.cominterstitial dilatation, but no signs of inflammation or
metabolic heart disease. No cardiotoxic medication could
be found in her previous medical history. Serum PCR for
cardiotropic viral pathogens including parvovirus B19,
coxsackie-A/B-virus, ECHO-virus, cytomegalovirus (CMV),
Epstein-Barrvirus (EBV),HHV-1,HHV-2,HHV-6, andHHV-8
was negative. No bacterial or fungal pathogen could be
isolated from repeatedly collected samples of body fluids.
At this point, the aetiologyof heart failure remainedunclear.
Anassociationbetweenglucagonomaandheart failure is
not known. However, we found one case report by Chang-
Chretien et al. (4)describinga54-year-old femalepatientwith
glucagonoma-induced cardiomyopathy. This patient pre-
sented an LVEF of 15% with no valvular disease, clean
coronary arteries, and in histopathology with only signs of
myocardial hypertrophyand interstitial fibrosis – very similar
toourpatient. Surgical removalof thetumour led tocomplete
normalisation of left ventricular function within 8 months.
As pathomechanism, the authors suspected tachycardio-
myopathy based on the chronotropic effect of glucagon.Treatment
Assuming that glucagonoma induced heart failure in our
patient, we started therapy with continuous infusion of
octreotide at a rate of 50 mg/h after an initial bolus of 50 mg,
as surgery was not an option. In the following days, left
ventricular (LV) function gradually improved, catechol-
amine treatment could be ended and the patient was
extubatedunder stable haemodynamic conditions.Within
3 weeks, LVEF recovered up to 45% with a cardiac index of
3.7 l/min per m2. We determined the levels of chromo-
graninA,which is used as biomarker inNETs and correlates
with hormone secretion (5). The levels of chromogranin A
were at 1100 mg/l (reference 19–150 mg/l) under stable
disease 1 year ago. Intriguingly, it was significantly
increased to 4174 mg/l at the point of acute heart failure,
and it markedly decreased after 1 day (1918 mg/l) and was
back to baseline after 3 weeks (1223 mg/l) upon continuous
octreotide treatment. Glucagon levels could not be
determined due to the lack of a reliable test.Discussion
The pathomechanism of glucagon-induced heart failure
remains subject to discussion. Glucagon binds to the
glucagon receptor in the plasma membrane and leads to
intracellular increase in cAMP with positive inotropic and
chronotropic effects. This effect is known to be indepen-
dent of b adrenergic receptors (6). Glucagon has been2
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Yet, it soon became obsolete due to its lacking impact on
chronic heart failure and the frequent occurrence of
gastrointestinal complications limiting its usefulness (8).
Hence, data on long-time effects of glucagon on the
myocardium aremissing. As cAMP activates protein kinase
A leading to phosphorylation of plasmalemmal L-type
calcium channels and therefore increasing calcium influx,
which in turn triggers release of calcium from intracellular
stores, we believe that long-term glucagon stimulation of
cardiomyocytesmay cause sarcoplasmic reticulumcalcium
leak, leading to the activation of hypertrophy and heart
failure signalling pathways (9) (10). Of note, myocardial
biopsy of our patient and of the patient described by
Chang-Chretien et al. revealed hypertrophy of myocytes.
In a retrospective view, we assume that congestive
heart failure started to develop in the course of primary
disease. Infection could have been a trigger for acute
decompensation, possibly aggravated by pausing antipro-
liferative therapy with everolimus and simultaneously
enhanced demand for octreotide, which may have led to
excessive tumour activity with overproduction of gluca-
gon. The trendof chromograninA levels is indicative, but is
not proving, because chromogranin A is a general product
of endocrine secretion. Limiting factors in the assessment
of chromogranin A in our patient are the use of proton
pump inhibitors and terminal kidney failure with haemo-
dialysis. However, both factors have been present years in
advance and cannot explain the significant relative
increase in chromogranin A at the point of acute heart
failure. Considering the results of the initial immunostain-
ing, we can assume that the tumour is indeed responsive
to octreotide, and it seems unlikely that other hormones
were causative for heart failure in this patient.
This case report demonstrates that glucagonoma can
be a cause for acute heart failure, which moreover is
reversible under continuous therapy with octreotide. It
supports the idea that there is a link between NET and
heart failure other than carcinoid heart disease. Therefore,
it seems feasible to suggest that cardiac function should be
monitored in a routine manner in all NET patients and
under specific circumstances even in closer intervals.
However, further studies are needed to elucidate the
underlying pathomechanisms.http://www.edmcasereports.comDeclaration of interest
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